Clinically approved for the management of HER2-positive breast cancer. trastuzumab-dkst (2017), trastuzumab-pkrb (2018-12), trastuzumab-dttb (2019-01), trastuzumab-qyyp (2019-03), trastuzumab-anns[28](2019-06-13). This evidence concerns the gene ERBB2 and breast cancer.